Literature DB >> 23463088

Guiding breast-conserving surgery in patients after neoadjuvant systemic therapy for breast cancer: a comparison of radioactive seed localization with the ROLL technique.

Mila Donker1, Caroline A Drukker, Renato A Valdés Olmos, Emiel J Th Rutgers, Claudette E Loo, Gabe S Sonke, Jelle Wesseling, Tanja Alderliesten, Marie-Jeanne T F D Vrancken Peeters.   

Abstract

BACKGROUND: Radioguided occult lesion localization (ROLL) with technetium-99 m colloid (ROLL-(99m)Tc) is commonly used to perform breast-conserving surgery in patients with nonpalpable breast tumors. Radioactive seed localization is a relatively new technique that localizes the tumor with a radioactive iodine-125 ((125)I) seed. The feasibility and outcome of these techniques after neoadjuvant systemic treatment has not been widely investigated.
METHODS: All patients treated with neoadjuvant systemic treatment between 2007 and 2010 in the Netherlands Cancer Institute who underwent breast-conserving surgery with the ROLL-(99m)Tc technique (n = 83) or with (125)I seed localization (n = 71) were analyzed. The weight of the resected specimen, the margins, and the percentage of patients requiring a second surgical intervention as a result of positive margins were assessed.
RESULTS: Patient and tumor characteristics and systemic treatment regimens were comparable between both groups. The median weight of the resected specimen (53 vs. 48 g), the median smallest margin (3.5 vs. 3.0 mm), and the risk for additional surgery for incomplete resections (7 vs. 8 %) did not differ significantly between patients treated with the ROLL-(99m)Tc technique and (125)I seed localization.
CONCLUSIONS: The ROLL-(99m)Tc technique and (125)I seed localization demonstrate comparable results when used to perform breast-conserving surgery after neoadjuvant systemic treatment. Because (125)I seed localization does not require additional radiological localization shortly before surgery, it simplifies surgery scheduling. Therefore, we prefer (125)I seed localization to perform breast-conserving surgery after neoadjuvant systemic treatment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23463088     DOI: 10.1245/s10434-013-2921-x

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  8 in total

1.  Breast-Conserving Therapy in Patients with cT3 Breast Cancer with Good Response to Neoadjuvant Systemic Therapy Results in Excellent Local Control: A Comprehensive Cancer Center Experience.

Authors:  Marieke E M van der Noordaa; Ileana Ioan; Emiel J Rutgers; Erik van Werkhoven; Claudette E Loo; Rosie Voorthuis; Jelle Wesseling; Japke van Urk; Terry Wiersma; Vincent Dezentje; Marie-Jeanne T F D Vrancken Peeters; Frederieke H van Duijnhoven
Journal:  Ann Surg Oncol       Date:  2021-05-12       Impact factor: 5.344

Review 2.  Does Tumor Marking Before Neoadjuvant Chemotherapy Helps Achieve Better Outcomes in Patients Undergoing Breast Conservative Surgery? A Systematic Review.

Authors:  Chandan Kumar Jha; Goonj Johri; Prashant Kumar Singh; Sanjay Kumar Yadav; Upasna Sinha
Journal:  Indian J Surg Oncol       Date:  2021-08-03

3.  Radioactive seed localization compared to wire localization in breast-conserving surgery: initial 6-month experience.

Authors:  James O Murphy; Tracy-Ann Moo; Tari A King; Kimberly J Van Zee; Kristine A Villegas; Michelle Stempel; Anne Eaton; Jean M St Germain; Elizabeth Morris; Monica Morrow
Journal:  Ann Surg Oncol       Date:  2013-08-14       Impact factor: 5.344

4.  Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial.

Authors:  Guido Henke; Michael Knauer; Karin Ribi; Stefanie Hayoz; Marie-Aline Gérard; Thomas Ruhstaller; Daniel R Zwahlen; Simone Muenst; Markus Ackerknecht; Hanne Hawle; Florian Fitzal; Michael Gnant; Zoltan Mátrai; Bettina Ballardini; Andreas Gyr; Christian Kurzeder; Walter P Weber
Journal:  Trials       Date:  2018-12-04       Impact factor: 2.279

5.  Three-year follow-up of de-escalated axillary treatment after neoadjuvant systemic therapy in clinically node-positive breast cancer: the MARI-protocol.

Authors:  Ariane A van Loevezijn; Marieke E M van der Noordaa; Marcel P M Stokkel; Erik D van Werkhoven; Emma J Groen; Claudette E Loo; Paula H M Elkhuizen; Gabe S Sonke; Nicola S Russell; Frederieke H van Duijnhoven; Marie-Jeanne T F D Vrancken Peeters
Journal:  Breast Cancer Res Treat       Date:  2022-03-03       Impact factor: 4.872

6.  Toolbox to Reduce Lumpectomy Reoperations and Improve Cosmetic Outcome in Breast Cancer Patients: The American Society of Breast Surgeons Consensus Conference.

Authors:  Jeffrey Landercasper; Deanna Attai; Dunya Atisha; Peter Beitsch; Linda Bosserman; Judy Boughey; Jodi Carter; Stephen Edge; Sheldon Feldman; Joshua Froman; Caprice Greenberg; Cary Kaufman; Monica Morrow; Barbara Pockaj; Melvin Silverstein; Lawrence Solin; Alicia Staley; Frank Vicini; Lee Wilke; Wei Yang; Hiram Cody
Journal:  Ann Surg Oncol       Date:  2015-07-28       Impact factor: 5.344

7.  Feasibility of preoperative (125)I seed-guided tumoural tracer injection using freehand SPECT for sentinel lymph node mapping in non-palpable breast cancer.

Authors:  Bas Pouw; Linda J de Wit-van der Veen; Daan Hellingman; Oscar R Brouwer; Marie-Jeanne Tfd Vrancken Peeters; Marcel Pm Stokkel; Renato A Valdés Olmos
Journal:  EJNMMI Res       Date:  2014-05-03       Impact factor: 3.138

8.  Breast-conserving surgery following neoadjuvant therapy-a systematic review on surgical outcomes.

Authors:  José H Volders; Vera L Negenborn; Pauline E Spronk; Nicole M A Krekel; Linda J Schoonmade; Sybren Meijer; Isabel T Rubio; M Petrousjka van den Tol
Journal:  Breast Cancer Res Treat       Date:  2017-12-06       Impact factor: 4.872

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.